Case Report
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jan 15, 2025; 16(1): 99135
Published online Jan 15, 2025. doi: 10.4239/wjd.v16.i1.99135
Application of Dorzagliatin in peritoneal dialysis patients with type 2 diabetes mellitus: A case report
Fang Chen, Bo An, Wen-Cheng An, Gang Fu, Wei Huang, Hui-Xian Yan
Fang Chen, Bo An, Wen-Cheng An, Wei Huang, Hui-Xian Yan, Department of Endocrinology, Beijing Haidian Hospital, Beijing 100080, China
Gang Fu, Department of Nephrology, Beijing Haidian Hospital, Beijing Haidian Section of Peking University Third Hospital, Beijing 100080, China
Author contributions: Chen F, An B, An WC, Huang W and Yan HX designed the research study; Chen F, An B and Yan HX performed the research, analyzed the data and wrote the manuscript; Chen F, Fu G and Yan HX participated in the revision of the manuscript; All authors have read and approved the final manuscript.
Informed consent statement: Informed consent was given by the patient.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui-Xian Yan, MD, PhD, Associate Chief Physician, Department of Endocrinology, Beijing Haidian Hospital, No. 29 Zhongguancun Street, Haidian District, Beijing 100080, China. yanhuixianhd@163.com
Received: July 15, 2024
Revised: September 17, 2024
Accepted: November 5, 2024
Published online: January 15, 2025
Processing time: 137 Days and 13.9 Hours
Core Tip

Core Tip: Treating diabetes in dialysis patients remains a challenge, with many hypoglycemic drugs requiring dose adjustments or avoidance in these patients. To our knowledge, this report is the first to use Dorzagliatin in the treatment of type 2 diabetes peritoneal dialysis patients with challenging glucose control. Dorzagliatin, a novel glucokinase activator primarily metabolized by the liver, exhibits no pharmacokinetic differences among patients with varying degrees of chronic kidney disease, has a high plasma protein binding rate, and may not be cleared by peritoneal dialysis, potentially offering a new glycemic control option for Type 2 diabetic patients on peritoneal dialysis.